Aurobindo Pharma Ltd (NSE:AUROPHARMA)
₹ 1265.15 13.85 (1.11%) Market Cap: 741.30 Bil Enterprise Value: 741.86 Bil PE Ratio: 23.36 PB Ratio: 2.48 GF Score: 94/100

Q2 2023 Aurobindo Pharma Ltd Earnings Call Transcript

Nov 14, 2022 / 03:00AM GMT
Release Date Price: ₹487.45 (-0.38%)
Operator

Hello, and good morning. Welcome to Aurobindo Pharma Quarter 2 FY '23 Earnings Call. (Operator Instructions)

Please note that this conference is being recorded. I now hand the conference over to Deepti Thakur for the opening remarks. Thank you, and over to you.

Deepti Thakur

Thank you, Aditya. Good morning, and a warm welcome to our second quarter FY '23 earnings call. I'm Deepti Thakur from the Investor Relations team. I would like to introduce my senior management team today on the call with us, represented by Dr. Satakarni Makkapati, CEO of Aurobindo Biosimilars, Vaccine and Peptides business; Mr. Yugandhar Puvvala, CEO of Eugia Pharma Specialities Limited; Mr. Sanjeev Dani, COO and Head Formulations Aurobindo Pharma Limited; Mr. S. Subramanian, CFO; and Mr. Swami Iyer, CEO of Aurobindo Pharma USA.

We will begin the call with summary highlights from the management followed by an interactive Q&A session. Please note that some of the matters we will discuss today are forward-looking, including and without limitations, statements relating to the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot